Page last updated: 2024-08-23

selegiline and Ophthalmoplegia, Progressive Supranuclear

selegiline has been researched along with Ophthalmoplegia, Progressive Supranuclear in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Chen, MJ; Ge, JJ; Jiao, FY; Ju, ZZ; Li, G; Li, XY; Liu, FT; Lu, JY; Sun, YM; Wang, J; Wu, JJ; Wu, P; Yao, RX; Yen, TC; Zuo, C	1
Comley, RA; Gauthier, S; Guiot, MC; Guo, Q; Harada, R; Kang, MS; Massarweh, G; Mathotaarachchi, S; Ng, KP; Okamura, N; Pascoal, TA; Rosa-Neto, P; Shin, M; Soucy, JP; Therriault, J	1
Kuhn, W; Müller, T	1

Reviews

1 review(s) available for selegiline and Ophthalmoplegia, Progressive Supranuclear

Article	Year
The clinical potential of Deprenyl in neurologic and psychiatric disorders. Journal of neural transmission. Supplementum, 1996, Volume: 48 Topics: Adult; Aged; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Antipsychotic Agents; Child; Clinical Trials as Topic; Cross-Over Studies; Depression; Double-Blind Method; Humans; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Narcolepsy; Nervous System Diseases; Neuroprotective Agents; Nootropic Agents; Parkinson Disease, Secondary; Schizophrenia; Selegiline; Supranuclear Palsy, Progressive; Tourette Syndrome; Treatment Outcome	1996

Article

Year

The clinical potential of Deprenyl in neurologic and psychiatric disorders.

Journal of neural transmission. Supplementum, 1996, Volume: 48

Topics: Adult; Aged; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Antipsychotic Agents; Child; Clinical Trials as Topic; Cross-Over Studies; Depression; Double-Blind Method; Humans; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Narcolepsy; Nervous System Diseases; Neuroprotective Agents; Nootropic Agents; Parkinson Disease, Secondary; Schizophrenia; Selegiline; Supranuclear Palsy, Progressive; Tourette Syndrome; Treatment Outcome

1996

Other Studies

2 other study(ies) available for selegiline and Ophthalmoplegia, Progressive Supranuclear

Article	Year
The Monoamine Oxidase-B Inhibitor Selegiline Does Not Affect Movement disorders : official journal of the Movement Disorder Society, 2023, Volume: 38, Issue:4 Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Positron-Emission Tomography; Selegiline; Supranuclear Palsy, Progressive; tau Proteins	2023
Monoamine oxidase B inhibitor, selegiline, reduces Alzheimer's research & therapy, 2017, Mar-31, Volume: 9, Issue:1 Topics: Aged; Alzheimer Disease; Aminopyridines; Autoradiography; Binding, Competitive; Brain; Cognitive Dysfunction; Drug Interactions; Female; Fluorine Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Selegiline; Supranuclear Palsy, Progressive; tau Proteins	2017

Article

Year

The Monoamine Oxidase-B Inhibitor Selegiline Does Not Affect

Movement disorders : official journal of the Movement Disorder Society, 2023, Volume: 38, Issue:4

Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Positron-Emission Tomography; Selegiline; Supranuclear Palsy, Progressive; tau Proteins

2023

Monoamine oxidase B inhibitor, selegiline, reduces

Alzheimer's research & therapy, 2017, Mar-31, Volume: 9, Issue:1

Topics: Aged; Alzheimer Disease; Aminopyridines; Autoradiography; Binding, Competitive; Brain; Cognitive Dysfunction; Drug Interactions; Female; Fluorine Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Selegiline; Supranuclear Palsy, Progressive; tau Proteins

2017